Tore Bengtsson Inventions, Patents and Patent Applications (2023)

Electric friction drive device and electric drive system

Patent number: 11603164

Abstract: The present invention relates to an electric drive system for a bike comprising a portable electric friction drive device and a bike bracket. A first drive device attachment point is located at a rear part of the friction drive device. A second drive device attachment point is located between the front part of the friction drive device and the rear part of the friction drive device. An inclination control arrangement is configured to control the inclination of the imaginary line between the second drive device attachment point and a contact point of the drive wheel by adjusting the tilt of the friction drive device over the second drive device attachment point. The bike has at least one wheel, comprising the electric drive system, wherein the drive wheel is arranged to be contactable to the tire of said wheel at said contact point.

Type: Grant

Filed: September 20, 2018

Date of Patent: March 14, 2023

Assignee: Zipforce AB

Inventors: Tore Bengtsson, Møns Bengtsson

Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia

Patent number: 11427539

Abstract: There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, ring A, m and n have meanings as provided in the description.

Type: Grant

Filed: September 13, 2018

Date of Patent: August 30, 2022

Assignee: ATROGI AB

Inventors: Benjamin Pelcman, Tore Bengtsson

HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA

Publication number: 20220194920

Abstract: There is herein provided a compound of formula I (I) or a pharmaceutically acceptable salt thereof, wherein the ring comprising Q1 to Q5, R1, m, X1 and ring A have meanings as provided in the description.

Type: Application

Filed: March 20, 2020

Publication date: June 23, 2022

Inventors: Benjamin Pelcman, Tore Bengtsson

HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA

Publication number: 20220152004

Abstract: There is herein provided a compound of formula I or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, ring A, n and y have meanings as provided in the description.

Type: Application

Filed: March 20, 2020

Publication date: May 19, 2022

Inventors: Benjamin Pelcman, Tore Bengtsson

HIGHLY STRUCTURED POROUS SILICA MATERIALS AND BIOLOGICAL USES THEREOF

Publication number: 20220135411

Abstract: There is provided herein a porous silica particle characterized by having a hierarchical pore structure wherein at least about 20% of the pores of the silica particle are of a size in the range of from about 7.0 to about 13.0 nm, and at least about 10% of the pores of the silica particle are of a size in the range of from about 0.5 to about 5.0 nm, and by having a particle size of from about 0.1 ?m to about 10.0 ?m. There is also provided compositions comprising such silica particles, process for their preparation, and medical and non-medical uses thereof.

Type: Application

Filed: March 1, 2019

Publication date: May 5, 2022

Inventors: Tore Bengtsson, Eric Johnston, Muhammad Naeem Iqbal

HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA

Publication number: 20220133703

Abstract: There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the ring containing Q1 to Q5, and the groups R1, R2 and R3, have meanings as provided in the description.

Type: Application

Filed: January 13, 2022

Publication date: May 5, 2022

Inventors: Benjamin Pelcman, Tore Bengtsson

COMBINATIONS OF ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES

Publication number: 20210338603

Abstract: There is herein provided pharmaceutical formulations and kits-of-parts comprising a ?2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, and a ?3-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof. This combination of active agents finds particular utility in the treatment of type 2 diabetes.

Type: Application

Filed: May 14, 2021

Publication date: November 4, 2021

Inventors: Benjamin Pelcman, Tore Bengtsson

HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA

Publication number: 20210030731

Abstract: There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the ring containing Q1 to Q5, and the groups R1, R2 and R3, have meanings as provided in the description.

Type: Application

Filed: September 13, 2018

Publication date: February 4, 2021

Inventors: Benjamin Pelcman, Tore Bengtsson

POROUS SILICA MATERIAL FOR USE AS A PHARMACEUTICAL OR DIETARY ACTIVE INGREDIENT

Publication number: 20200390703

Abstract: A porous silica material for use as a pharmaceutical or dietary active ingredient having pores in the mesoscale range (2-50 nm), wherein the average pore size of the pores in the mesoscale range is in the range of 2 to 25 nm, and the pore size distribution (PSD) in the mesoscale range is such that at least 80% of the pores fall within the range of 2 to 25 nm.

Type: Application

Filed: June 26, 2020

Publication date: December 17, 2020

Inventors: Robert Csikasz, Tore Bengtsson, Natalia Kupferschmidt, Alfonso E. Garcia-Bennett

COMBINATIONS OF ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES

Publication number: 20200315993

Abstract: There is herein provided pharmaceutical formulations and kits-of-parts comprising a ?2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, and a ?3-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof. This combination of active agents finds particular utility in the treatment of type 2 diabetes.

Type: Application

Filed: June 22, 2020

Publication date: October 8, 2020

Inventors: Benjamin Pelcman, Tore Bengtsson

BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA

Publication number: 20200277259

Abstract: There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, ring A, m and n have meanings as provided in the description.

Type: Application

Filed: September 13, 2018

Publication date: September 3, 2020

Inventors: Benjamin Pelcman, Tore Bengtsson

CHIRAL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCEMIA

Publication number: 20200268687

Abstract: There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4 and n have meanings as provided in the description.

Type: Application

Filed: September 13, 2018

Publication date: August 27, 2020

Inventors: Benjamin Pelcman, Tore Bengtsson

FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA

Publication number: 20200268688

Abstract: There is herein provided a compound of formula (I).

Type: Application

Filed: September 13, 2018

Publication date: August 27, 2020

Inventors: Benjamin Pelcman, Tore Bengtsson

Electric Friction Drive Device and Electric Drive System

Publication number: 20200231248

Abstract: The present invention relates to an electric drive system for a bike comprising a portable electric friction drive device (1) and a bike bracket (13) configured to be mounted on a bike. A first drive device attachment point (3?) is located at a rear part of the friction drive device. A second drive device attachment point (4?) is located between the front part of the friction drive device and the rear part of the friction drive device so that the friction drive device is configured to rest against the second bracket attachment point (4). An inclination control arrangement (2) is configured to control the inclination of the imaginary line between the second drive device attachment point and a contact point (9?) of the drive wheel (9) by adjusting the tilt of the friction drive device over the second drive device attachment point. Further, the invention relates to a portable electric friction drive device.

Type: Application

Filed: September 20, 2018

Publication date: July 23, 2020

Inventors: Tore Bengtsson, Måns Bengtsson

Porous silica material for use as a pharmaceutical or dietary active ingredient

Patent number: 10695294

Abstract: A porous silica material for use as a pharmaceutical or dietary active ingredient having pores in the mesoscale range (2-50 nm), wherein the average pore size of the pores in the mesoscale range is in the range of 2 to 25 nm, and the pore size distribution (PSD) in the mesoscale range is such that at least 80% of the pores fall within the range of 2 to 25 nm.

Type: Grant

Filed: November 6, 2013

Date of Patent: June 30, 2020

Assignee: Sigrid Therapeutics AB

Inventors: Robert Csikasz, Tore Bengtsson, Natalia Kupferschmidt, Alfonso E. Garcia-Bennett

COMBINATIONS OF ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES

Publication number: 20190314301

Abstract: There is herein provided pharmaceutical formulations and kits-of-parts comprising a ?2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, and a ?3-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof. This combination of active agents finds particular utility in the treatment of type 2 diabetes.

Type: Application

Filed: July 13, 2017

Publication date: October 17, 2019

Applicant: Atrogi AB

Inventors: Benjamin PELCMAN, Tore BENGTSSON

Screening method, a kit, a method of treatment and a compound for use in a method of treatement

Patent number: 10288602

Abstract: A method of screening for a candidate compound for the treatment of a condition involving dysregulation of metabolism in a mammal, said method comprising bringing a compound into contact with at least one population of cells, comprising cells that express mTOR and Akt and that are capable of activating mTORC2 and Akt; determining mTORC2 activity and Akt activity in cells brought into contact with the compound, and identifying the candidate compound based on the determined mTORC2 activity and Akt activity. A kit for use in such a method of. A compound for use in a method of treatment of a condition involving dysregulation of metabolism in a mammal, and a method of treatment of such a condition.

Type: Grant

Filed: October 9, 2017

Date of Patent: May 14, 2019

Assignee: ATROGI AB

Inventor: Tore Bengtsson

COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA

Publication number: 20190119196

Abstract: There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of hyperglycaemia or a disorder characterized by hyperglycaemia, such as type 2 diabetes, wherein X, R1, R2, R3 and n have meanings as provided in the description.

Type: Application

Filed: March 7, 2017

Publication date: April 25, 2019

Inventors: Benjamin Pelcman, Tore Bengtsson

Screening Method, a Kit, A method of Treatment and a Compound for Use in a Method of Treatement

Publication number: 20180095072

Abstract: A method of screening for a candidate compound for the treatment of a condition involving dysregulation of metabolism in a mammal, said method comprising bringing a compound into contact with at least one population of cells, comprising cells that express mTOR and Akt and that are capable of activating mTORC2 and Akt; determining mTORC2 activity and Akt activity in cells brought into contact with the compound, and identifying the candidate compound based on the determined mTORC2 activity and Akt activity. A kit for use in such a method of. A compound for use in a method of treatment of a condition involving dysregulation of metabolism in a mammal, and a method of treatment of such a condition.

Type: Application

Filed: October 9, 2017

Publication date: April 5, 2018

Inventor: Tore Bengtsson

Screening method, a kit, a method of treatment and a compound for use in a method of treatment

Patent number: 9891212

Abstract: A method to identify a candidate compound for use in the treatment of a condition involving dysregulation of glucose homeostasis or of glucose uptake in a mammal, by identifying a candidate compound that causes an increase in translocation of GLUT without causing an increase in the production of cAMP. A kit for use in such a method. A method of treatment of a condition involving dysregulation of glucose homeostasis or of glucose uptake in a mammal and a compound for use in such a method.

Type: Grant

Filed: December 16, 2013

Date of Patent: February 13, 2018

Assignee: ATROGI AB

Inventor: Tore Bengtsson